Connetics Corporation (NASDAQ: CNCT) announced a positive outcome in a Phase III clinical trial of Extina (ketoconazole) Foam, 2%, formulated ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE